PharmiWeb.com - Global Pharma News & Resources
01-Nov-2018

Company Profile for Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com.

Company:   Inflection Biosciences Ltd
 

Headquarters Address:

 

Suite 15, Anglesea House, Carysfort Avenue,
Blackrock, Co. Dublin

 

Dublin
Ireland
 
Main Telephone: +35314003615
 
Website:

www.inflectionbio.com

 
Type of Organization: Private
 
Industry: Biotechnology
 
Key Executives: CEO: Darren Cunningham
Director of R&D: Michael O'Neill
 
CEO
Contact: Darren Cunningham
Phone: +35314003615
Email:

dcunningham@inflectionbio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005653/en/

Editor Details

Last Updated: 01-Nov-2018